Trials / Completed
CompletedNCT02974153
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,121 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALD403 (Eptinezumab) | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-11-01
- Completion
- 2018-04-01
- First posted
- 2016-11-28
- Last updated
- 2020-06-09
- Results posted
- 2020-06-09
Locations
144 sites across 13 countries: United States, Belgium, Czechia, Denmark, Georgia, Germany, Hungary, Italy, Russia, Slovakia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02974153. Inclusion in this directory is not an endorsement.